Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q4 2023 call → NOWe need to analyze the transcript for the described phenomenon. The question asks: does management describe that its counterparties are already losing something real and ongoing for as long as they do not have what this company provides, and that this accumulating loss is already visible in how those parties are behaving toward the company today? We need to find evidence of both halves: (1) a running meter on the other side (cost/loss/forfeited gain accumulating until company delivers), and (2) counterparties already acting like the meter is running (pressing, paying more, etc.). Also that this dynamic is generating meaningful business. Let's scan the transcript. Management talks about many products. We need to find a situation where the counterparty (customer, partner) is losing something real and ongoing until they get Pfizer's product, and that they are already behaving accordingly. Possible candidates: - Vaccines? For example, RSV vaccine Abrysvo? They talk about market share, but not about counterparty losing something ongoing. - Oncology? PADCEV? They talk about launch, but not about counterparty's accumulating loss. - Seagen? Not really. - Etrasimod? They mention impairment. - They talk about Nurtec, etc. Look for language like "running meter", "cost of delay", "leaving money on the table", "racing against time", etc. Search for phrases: "every period", "until", "while they wait", "cost", "penalty", "idle", "lose", "loss". Also note the question: "management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING ... for as long as they do not have what this company provides". That is a very specific pattern. For example, a customer who is incurring losses due to lack of the product. I see one possible area: GBT-601 for sickle cell disease? They talk about data showing blood parameters approaching normal. But not about ongoing losses. Another: Comirnaty? They talk about market dynamics, but not that counterparties are losing something. Maybe the closest is in the discussion about Prevnar? They talk about adult market shrinking, pediatric growth, but not about counterparties' running meter. What about the discussion about "co-administration with flu vaccines" - they say there is opportunity to increase vaccination uptake, but that's about Pfizer's opportunity.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...